Global Blood Therapeutics, Inc.

Peter Michael Rademacher

Zhe Li

Qing Xu

Calvin Wesley Yee

Carsten Alt

Shahul Nilar

Brian Walter Metcalf

The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I or I' and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.

Cycloalkyl pyrimidines as ferroportin inhibitors

The subject matter described herein is directed to Ferroportin inhibitor compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis. The compounds of Formula I and pharmaceutical salts thereof have the following structure: wherein R, R, R, X, X, X, X, Y, Y, and Yare as described herein.

Ferroportin inhibitors and methods of use

Growing community of inventors

San Francisco, CA, United States of America

Peter Michael Rademacher